Pulmonx Co. (NASDAQ:LUNG) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Pulmonx Co. (NASDAQ:LUNG) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $12.75.

A number of brokerages have issued reports on LUNG. Stifel Nicolaus lowered their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Wells Fargo & Company decreased their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Finally, Citigroup reissued a “neutral” rating and issued a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th.

Pulmonx Price Performance

Shares of NASDAQ LUNG opened at $6.76 on Friday. Pulmonx has a 52 week low of $5.46 and a 52 week high of $14.84. The business’s 50 day moving average price is $6.55 and its 200 day moving average price is $6.87. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The firm has a market cap of $266.94 million, a P/E ratio of -4.60 and a beta of 0.66.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same period in the previous year, the firm posted ($0.39) earnings per share. On average, sell-side analysts expect that Pulmonx will post -1.53 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Geoffrey Beran Rose sold 4,376 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.18, for a total transaction of $27,043.68. Following the completion of the transaction, the insider now directly owns 291,057 shares in the company, valued at $1,798,732.26. This trade represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the completion of the sale, the director now owns 1,071,974 shares in the company, valued at $7,107,187.62. This represents a 1.83 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,873 shares of company stock valued at $324,070. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Pulmonx

A number of large investors have recently modified their holdings of LUNG. Barclays PLC lifted its stake in Pulmonx by 1.8% in the third quarter. Barclays PLC now owns 94,109 shares of the company’s stock worth $780,000 after acquiring an additional 1,679 shares during the last quarter. 272 Capital LP acquired a new stake in shares of Pulmonx in the 3rd quarter valued at $25,000. nVerses Capital LLC purchased a new stake in shares of Pulmonx during the 3rd quarter worth $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Pulmonx during the 2nd quarter worth $37,000. Finally, Victory Capital Management Inc. grew its stake in shares of Pulmonx by 1.0% during the second quarter. Victory Capital Management Inc. now owns 834,301 shares of the company’s stock worth $5,289,000 after purchasing an additional 8,004 shares in the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.